Impact of the 13-valent conjugated pneumococcal vaccine on the direct costs of invasive pneumococcal disease requiring hospital admission in children aged

Hernández, SergiNavas, EncarnaAznar Lou, IgnacioCiruela, PilarGarcía García, Juan JoséMoraga Llop, Fernando A.Muñoz Almagro, CarmenCodina Grau, Maria Gemmade Sevilla, Mariona F.González Peris, SebastiàEsteva, CristinaPlanes, Ana MaríaIzquierdo, ConchitaMartínez Osorio, JohannaCampins Martí, MagdaUriona, SoniaSalleras i Sanmartí, LluísSerrano Blanco, AntoniJané, MireiaDomínguez García, Àngela2021-03-102021-03-102020-07-152076-393Xhttps://hdl.handle.net/2445/174866The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect of pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007-2009 (PCV7 period) and 2012-2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%, respectively). During 2007-2015, the costs associated with PCV7 serotypes (Pearson coeffcient (Pc) = 􀀀0.79; p = 0.036) and additional PCV13 serotypes (Pc = 􀀀0.75; p = 0.05) decreased, but those of other serotypes did not (Pc = 0.23 p = 0.62). The total mean cost of IPD increased in the PCV13 period by 31.4% (¿3016.1 vs. ¿3963.9), mainly due to ICU stay (77.4%; ¿1051.4 vs. ¿1865.6). During the PCV13 period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.15 p.application/pdfengcc-by (c) Hernández, Sergi et al., 2020http://creativecommons.org/licenses/by/3.0/esVacuna antipneumocòccicaInfantsPneumococcal vaccineChildrenImpact of the 13-valent conjugated pneumococcal vaccine on the direct costs of invasive pneumococcal disease requiring hospital admission in children aged < 5 years. A prospective studyinfo:eu-repo/semantics/article7026922021-03-10info:eu-repo/semantics/openAccess32679762